Multimodal Treatments for Resectable Esophagogastric Junction Cancer: A Bayesian Network Meta-analysis

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2023 Mar 19

PMID 36934163

Authors

Pengfei Shao

ShaZhen NiMa

Yang Tse

Zhuoma Suolang

Cangjue Pubu

Affiliations

Soon will be listed here.

Abstract

Purpose: To comprehensively investigate the optimal multimodal treatment of resectable esophagogastric junction (EGJ) cancer.

Methods: PubMed, Embase, Cochrane Library and Web of Science were searched until March 11, 2022. The outcomes were overall survival (OS), locoregional and distant recurrence, and R0 resection. Network plots, forest plots and league tables were drawn for each outcome. Rank probabilities for different treatments in each outcome were also depicted.

Results: A total of 23 studies with 18,319 EGJ participants were included. No significant differences in OS between any two of the 6 treatments. Perioperative chemoradiotherapy (pCRT) had the highest probability (36.03%) to be the optimal treatment as regards OS. Patients undergoing pCRT had a significantly lower incidence of locoregional recurrence than those undergoing adjuvant chemotherapy (aCT), neoadjuvant chemotherapy (nCT), perioperative chemotherapy (pCT), or surgery alone (S). Patients with pCRT had the greatest likelihood (68.86%) to have the lowest incidence of locoregional recurrence. Comparable impacts of the 6 treatments on the incidence of distant recurrence, and pCRT was most likely (46.65%) to be the optimal treatment with respect to distant recurrence. Neoadjuvant CRT (nCRT) was associated with a significantly increased incidence of R0 resection compared with nCT or S, and nCRT had the highest probability (97.68%) to be the best therapy regarding R0 resection.

Conclusion: For patients with resectable EGJ cancer, pCRT may be the optimal multimodal treatment regarding survival and recurrence.

References

Siewert J, Stein H . Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998; 85(11):1457-9. DOI: 10.1046/j.1365-2168.1998.00940.x. View

Chevallay M, Bollschweiler E, Chandramohan S, Schmidt T, Koch O, Demanzoni G . Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Ann N Y Acad Sci. 2018; 1434(1):132-138. DOI: 10.1111/nyas.13954. View

Stein H, Feith M, Siewert J . Cancer of the esophagogastric junction. Surg Oncol. 2001; 9(1):35-41. DOI: 10.1016/s0960-7404(00)00021-9. View

Yanagimoto Y, Kurokawa Y, Doki Y, Yoshikawa T, Boku N, Terashima M . Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. Jpn J Clin Oncol. 2022; 52(5):417-424. DOI: 10.1093/jjco/hyac019. View

Bystricky B, Okines A, Cunningham D . Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011; 71(5):541-55. DOI: 10.2165/11585460-000000000-00000. View

van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84. DOI: 10.1056/NEJMoa1112088. View

Ychou M, Boige V, Pignon J, Conroy T, Bouche O, Lebreton G . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715-21. DOI: 10.1200/JCO.2010.33.0597. View

Al-Batran S, Hofheinz R, Pauligk C, Kopp H, Haag G, Luley K . Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.... Lancet Oncol. 2016; 17(12):1697-1708. DOI: 10.1016/S1470-2045(16)30531-9. View

Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge Henegouwen M, Wijnhoven B . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. View

10.

Vos E, Carr R, Hsu M, Nakauchi M, Nobel T, Russo A . Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. Br J Surg. 2021; 108(11):1332-1340. PMC: 8599637. DOI: 10.1093/bjs/znab228. View

11.

Graham A, Finley R, Clifton J, Evans K, Fradet G . Surgical management of adenocarcinoma of the cardia. Am J Surg. 1998; 175(5):418-21. DOI: 10.1016/S0002-9610(98)00040-3. View

12.

Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S . Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. BMC Surg. 2021; 21(1):137. PMC: 7972233. DOI: 10.1186/s12893-021-01136-z. View

13.

Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M . Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up. World J Gastroenterol. 2017; 23(15):2723-2730. PMC: 5403751. DOI: 10.3748/wjg.v23.i15.2723. View

14.

Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K . Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol. 2019; 11:1758835919838963. PMC: 6446435. DOI: 10.1177/1758835919838963. View

15.

Achiam M, Jensen L, Larsson H, Jensen L, Larsen A, Holm J . Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone. Scand J Surg. 2015; 105(1):22-8. DOI: 10.1177/1457496915577021. View

16.

Bekkar S, Gronnier C, Messager M, Robb W, Piessen G, Mariette C . The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. Ann Thorac Surg. 2013; 97(1):303-10. DOI: 10.1016/j.athoracsur.2013.09.010. View

17.

Favi F, Bollschweiler E, Berlth F, Plum P, Hescheler D, Alakus H . Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. Eur J Surg Oncol. 2017; 43(8):1572-1580. DOI: 10.1016/j.ejso.2017.06.003. View

18.

Ito H, Clancy T, Osteen R, Swanson R, Bueno R, Sugarbaker D . Adenocarcinoma of the gastric cardia: what is the optimal surgical approach?. J Am Coll Surg. 2004; 199(6):880-6. DOI: 10.1016/j.jamcollsurg.2004.08.015. View

19.

Kofoed S, Muhic A, Baeksgaard L, Jendresen M, Gustafsen J, Holm J . Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg. 2012; 101(1):26-31. DOI: 10.1177/145749691210100106. View

20.

Marica C, Birla R, Marica R, Panaitescu E, Constantinoiu S . Neoadjuvant Radiochemotherapy for Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma. Chirurgia (Bucur). 2018; 113(2):192-201. DOI: 10.21614/chirurgia.113.2.192. View